-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target

Benzinga·09/14/2026 12:43:43
Listen to the news
Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperform and maintains $22 price target.